n BACKGROUND AND OBJECTIVE: To determine the efficacy of off-label intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal vascular diseases. n RESULTS: Thirty-five eyes of 33 patients were treated with IVB alone or in combination with other treatments for choroidal neovascularization, Coats' disease, familial exudative vitreoretinopathy, and various other indications. IVB was used in 24 eyes to reduce excess retinal fluid and exudation. Mean Snellen visual acuity improved from 20/170 at baseline to 20/100 at 1 month (P = .006), 20/80 at 3 months (P = .006), and 20/50 at 6 months (P = .023). Central macular thickness improved from 356 µm at baseline to 287 µm at 6 months (P = .028). IVB was used in 11 eyes to control peripheral retinal neovascularization and iris rubeosis. Although IVB reduced vascular engorgement, it did not prevent the progression of preretinal tractional forces. Mean visual acuity was maintained at each time point. No systemic or ocular adverse events were directly attributable to IVB in any patient.
INTRODUCTION
Vascular endothelial growth factor-A (VEGF-A) is a potent hypoxia-induced angiogenic and vasopermeability factor implicated in multiple ocular vascular diseases. [1] [2] [3] Visual loss results from retinal ischemia or as a complication of VEGF-mediated ocular neovascularization and vascular leakage of fluid, blood, and exudates. 4 Experimentally, pharmacologic blockade of VEGF-A regresses neovascularization and contributes to the resolution of intraretinal and subretinal fluid, often resulting in stabilization or improvement of visual acuity. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Ocular neovascularization and vascular exudation have been reported in pediatric retinal and choroidal diseases, including retinopathy of prematurity (ROP), choroidal neovascularization (CNV), familial exudative vitreoretinopathy, and Coats' disease (idiopathic retinal telangiectasia). [24] [25] [26] [27] [28] These diseases are uncommon, but pharmacotherapeutics are lacking and the visual prognosis is often poor despite aggressive laser and surgical intervention. 24, [29] [30] [31] Recent work has confirmed the role of VEGF in their pathogenesis.
Prospective studies investigating intravitreal anti-VEGF medications in a pediatric population have met with resistance due to concerns about ocular and systemic toxicity, especially the theoretical possibility of interference with vascular and neurologic development. Because premature infants with ROP may represent a more at-risk population for these complications, they were excluded from this study. We therefore retrospectively evaluated the safety and efficacy of IVB for children of various ages with retinal and choroidal vascular diseases other than ROP.
PATIENTS AND METHODS
After obtaining Institutional Review Board approval for this analysis, we performed a retrospective, noncomparative, open-label, interventional, consecutive case series review of all eyes from patients younger than 18 years of age who received off-label intravitreal bevacizumab (IVB) at the Bascom Palmer Eye Institute between January 1, 2005, and January 1, 2008. Eyes treated with intravitreal bevacizumab for ROP were excluded from the study. The charts were reviewed for patient demographics, eye studied, lens status, ocular history, indication for IVB, comorbid systemic and ocular conditions, visual acuity by age-appropriate testing, blood pressure before and after injection, and systemic and ocular complications following intravitreal injection. Funduscopic images taken by RetCam II (Clarity Medical Systems, Inc., Pleasanton, CA) and Topcon retinal cameras (Topcon Medical Systems, Inc., Paramus, NJ) were reviewed for the presence of retinal or choroidal neovascularization or their sequelae: exudates, hemorrhage, or intraretinal or subretinal fluid. Clinical and photographic findings were correlated with a combination of optical coherence tomography (Zeiss Stratus OCT 3; Carl Zeiss Meditec, Dublin, CA), fluorescein angiography, or indocyanine green angiography when available. Central macular thickness was calculated from the central 1-mm subfield of radial line scans by the proprietary software. A-and B-scan ultrasonography (System ABDv2; Innovative Imaging Inc., Sacramento, CA) were performed when media opacity prohibited funduscopic detail, retinal detachment was present or suspected, and any suspected ocular mass was present.
Informed consent was obtained from the families of all patients after a thorough discussion about alternative treatments, known and theoretical risks of bevacizumab, and the experimental nature of its intravitreal administration. Physical examinations were performed by the patients' pediatricians prior to initiation of treatment and periodically at their discretion thereafter. Pregnancy tests were obtained from girls who had undergone menarche. Blood pressure was measured prior to each injection and at subsequent examinations. All procedures were performed in compliance with the Declaration of Helsinki. Examinations were performed in the clinic or under anesthesia in the operating room depending on the age and level of compliance of the patient. RetCam II photography, Aand B-scan ultrasonography, or both were performed on all children receiving the examination under anesthesia.
Injections were performed by three vitreoretinal surgeons using a standardized technique. Cooperative patients received injections in a clinical setting without sedation. Patients who could not cooperate had injections performed following examination while under anesthesia. A sterile speculum, betadine prep, and sterile gloves were used in all cases. In patients undergoing vitrectomy, IVB was administered at the conclusion of the procedure after sclerotomies had been closed. The location of the pars plana was judged by the vitreoretinal surgeon 32 and marked with a sterile caliper, and 1.25 mg of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) was injected with a 30-gauge 
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half-inch needle angled parallel to the visual axis to avoid the crystalline lens and peripheral retina. Retinal perfusion was verified via indirect ophthalmoscopy and the patient was observed until the intraocular pressure (IOP) was less than 30 mm Hg (Tonopen XL; Reichert Ophthalmic Instruments, Depew, NY). A paracentesis was performed in patients with glaucoma following the injection with a 30-gauge needle. Patients were given one drop of a topical antibiotic and their families were instructed to apply it four times a day for 3 days and counseled on signs of infection. Subsequent examinations were performed within 4 weeks and thereafter at the discretion of the treating surgeon.
Statistical Analysis
Snellen visual acuities were converted to logarithm of the minimum angle of resolution acuities for data analysis. Acuities too poor or otherwise unable to be assessed with Snellen charts were converted using the following convention: blinks to light and fixes and follows (20/200); hand motions (20/20000); and no fixation or following and no light perception (20/200000) . Logarithm of the minimum angle of resolution acuities and central macular thicknesses at 1, 3, and 6 months were compared with baseline values using the paired t test and the nonparametric paired Wilcoxon test with SSPS 17 software (IBM, Chicago, IL). Both eyes of two patients were included as if they were independent observations in this analysis; however, a second analysis including only one eye per patient gave the same results. There were no differences with respect to statistical significance between the two sets of analyses.
RESULTS
Thirty-five eyes of 33 patients (Table 1 ) with a mean age of 9.3 years (range: 2 months to 17 years) received a total of 83 injections of IVB (average: 2.4; range: 1 to 8 per eye) with a mean follow-up of 372 days (median: 405 days; range: 20 to 765 days). Thirteen patients were boys and 20 were girls. The right eye was treated in 18 patients, the left eye was treated in 17 patients, and both eyes were treated in 2 patients. Fourteen (40%) of 35 eyes required reinjection with IVB at a mean of 89 days (median: 42 days) following the initial injection. Thirty (86%) of 35 eyes were phakic prior to the injection and 5 (14%) eyes were pseudophakic. IVB was given as monotherapy in 14 (40%) eyes and in combination with vitrectomy, laser, or intravitreal triamcinolone acetonide (Kenalog; Bristol-Myers Squibb, New York, NY) in 21 (60%) eyes. Seven (20%) eyes had prior ocular surgery, 7 (20%) eyes received IVB at the conclusion of vitrectomy or scleral buckling, and 6 (17.1%) eyes required subsequent vitrectomy for related to proliferative vitreoretinopahty recurrent retinal detachment.
Indications for IVB included excess intraretinal or subretinal fluid and exudation ( Fig. 1 ) and neovascular- ization of the peripheral retina or iris (Fig. 2) . Twentyfour eyes with excess fluid that received 60 injections of IVB (mean: 2.6; median: 2.0; range: 1 to 8 per eye) had a statistically significant improvement in visual acuity with one or more injections (P < .05). Mean visual acuity improved from baseline 20/170 (range: 20/20 to no light perception) to 20/80 at 1 month, 20/50 at 3 months, and 20/60 at 6 months ( Table 2) . Mean baseline central macular thickness was 375 µm, which improved postoperatively to 321 µm at 1 month, 293 µm at 3 months, and 287 µm at 6 months (P = .028). Eleven eyes received IVB in combination with other treatments to control neovascularization of the peripheral retina or iris and their sequelae. Mean visual acuity remained stable throughout follow-up.
As a subgroup, older children treated with IVB for CNV showed the most improvement in mean visual acuity (Table 3) . Patients with Coats' disease or familial exudative vitreoretinopathy had stable visual acuity and no group lost visual acuity compared with baseline. One patient with sickle cell retinopathy and central retinal vein occlusion with cystoid macular edema showed dramatic improvement in mean central macular thickness from 811 to 156 µm at 6 months after a single injection of IVB.
There were no observed systemic side effects from IVB. Mean baseline blood pressure was 106/65 and did not increase in patients who received subsequent injections (P > .05). No neurologic deficits or thromboembolic events occurred in any patient.
Ocular side effects were limited and none could solely be attributed IVB. Patients who received IVB as monotherapy did not experience ocular complications. Of those receiving IVB in combination with another therapy, preexisting tractional retinal detachment progressed despite laser treatment and IVB in three patients with familial exudative vitreoretinopathy. Cataract occurred in one patient with familial exudative vitreoretinopathy who received IVB at the conclusion of vitrectomy with gas tamponade. Mean IOP remained unchanged at 1 month (P = .231) and 3 months (P = .393) following injection of IVB. IOP was elevated in three patients, one with epithelial downgrowth and two who received intravitreal triamcinolone acetonide 2 months prior. The former progressed to a visual acuity of no light perception due to epithelial downgrowth despite extensive surgery and was enucleated. The latter two patients had elevated IOP attributable to steroid response to intravitreal triamcinolone acetonide.
No intraocular inflammation or endophthalmitis was observed.
DISCUSSION
VEGF physiologically plays a role in vasculogenesis, brain development, and neuroprotection in the setting of ischemia. [33] [34] [35] [36] Complications of intravenous bevacizumab include hypertension, gastrointestinal bleeding or perforation, cerebrovascular accident, and glomerular injury. 37 Systemic complications of IVB have been reported in approximately 1% of adult patients and their frequency in a pediatric population is unknown. 38, 39 Ocular complications include local pain and injection, transiently increased IOP, inflammation, and endophthalmitis. The greater relative size of the lens and the incomplete formation of the pars plana may contribute to a higher incidence of direct needle injury to the lens or retina in younger pediatric patients. 39 The largest retrospective series to date investigating the use of IVB in a pediatric population was reported by Mintz-Hittner et al., who performed bilateral injections of IVB in premature infants with threshold ROP. 40 The authors reported that no infant with a congenital systemic or ocular anomaly was included in their series, yet most were described as having preexisting moderate to severe central nervous system problems prior to treatment. Despite a remarkable demonstration of efficacy, we cannot make conclusions about systemic safety from this study. We observed no systemic adverse events, but our study lacks sufficient sample size to detect rare complications. 41 Bevacizumab was chosen among other VEGF inhibitors for theoretical advantages in safety and efficacy. It is a larger molecule than pegaptanib, ranibizumab, or VEGF Trap-Eye (Regeneron Pharmaceuticals, Inc., Tarrytown, NY), making it theoretically more difficult to penetrate the retina and break through the bloodretinal barrier by diffusion. In a rabbit model, only 1:1,000 of the bevacizumab administered to the vitreous reached the circulation. 42 However, VEGF is an extremely potent vasopermeability factor that may disrupt the inner blood-retinal barrier, potentially allowing bevacizumab to escape into the systemic circulation from eyes with pathologic vascular leakage and hyperpermeability. This may be counteracted by the action of IVB and the lack of vitreous liquefaction in younger patients, which may make escape of the drug from the vitreous more difficult and prolong the drug's half-life, thereby reducing the frequency of injections required to control the disease in nonvitrectomized eyes. 40 In this retrospective study, we observed the effects of IVB alone or in combination with conventional therapies in several pediatric retinal and choroidal vascular diseases. The visual prognosis for the indicated diseases using conventional treatment is poor. Unsatisfactory anatomic and visual outcomes using conventional treatment modalities and recognition of a common role of VEGF in retinal and choroidal vascular diseases have driven clinicians to search for alternative therapeutic options.
The poor prognosis of juxtafoveal and subfoveal CNV in age-related macular degeneration has been well elucidated in the Macular Photocoagulation Studies. 43, 44 Natural history studies in children with CNV from multiple causes demonstrate variable visual outcomes from subretinal scarring and photoreceptor degeneration. 45, 46 Multiple studies have demonstrated the efficacy of IVB in the treatment of CNV in adults. [19] [20] [21] [22] [47] [48] [49] As a subgroup, patients in our study treated with IVB for CNV had the greatest improvement in visual acuity and central macular thickness compared with baseline. Regardless of the primary disease, the response to IVB was similar among all patients in the study. However, children with monocular disease may present later in their disease course than adults, limiting visual recovery.
Sun et al. reported elevated vitreous levels of VEGF in a patient with stage 3A Coats' disease with exudative retinal detachment. 50 Treatment with intravitreal pegaptanib reduced vitreous levels of VEGF and decreased subretinal fluid and exudates. In our subgroup with Coats' disease, IVB produced modest reductions in subretinal and intraretinal fluid and exudation. Visual acuity and central macular thickness remained stable throughout follow-up, but gains were limited by extensive macular exudation, which was present in all but one patient in our cohort. The natural history of Coats' disease is especially poor when patients present with later stages of the disease. In a series of 117 eyes with Coats' disease described by Shields et al. in the 2000 Proctor Lecture, only 20% of eyes had a visual acuity better than 20/200 despite treatment, and 16% required enucleation. 24 Pendergast and Trese reported a similarly poor prognosis in surgically treated eyes with familial exudative vitreoretinopathy. 29 Specifically, 62.1% of eyes had anatomic reattachment of the macula and only 34.5% of eyes achieved a visual acuity of 20/100 or better. Mutations in the frizzled 4 gene of the Wnt receptor, which has been implicated in angiogenesis, have been detected in families with familial exudative vitreoretinopathy, supporting a VEGF-mediated basis for the disease with implications for pharmacotherapeutics. 51 Our results with familial exudative vitreoretinopathy were mixed. Patients who presented prior to tractional retinal detachment were noted to have regression of peripheral retinal neovascularization without consequence (Fig. 3) . Patients with stage 3 or higher had progression of the tractional retinal detachment despite laser treatment and IVB and required vitrectomy. In these patients, the utility of IVB is questionable. Patients with extensive posterior neovascularization from proliferative diabetic retinopathy have been observed to undergo fibrotic transformation of the neovascular tissue. 52 This "crunch" phenomenon results in visual loss from macular tractional retinal detachment. Blockage of VEGF in the setting of ischemia upregulates connective tissue growth factor, which stimulates fibrosis of retinal neovascularization. 53 This effect is not unique to IVB; tractional retinal detachment has been observed in patients with aggressive posterior ROP and patients with familial exudative vitreoretinopathy following laser treatment. 30, 54 The effect of IVB alone in patients with familial exudative vitreoretinopathy is unknown, because laser ablation of the peripheral ischemic retina was performed concurrently with IVB in all our cases of familial exudative vitreoretinopathy. Unlike ROP in which neovascularization occurs during a discrete window, patients with familial exudative vitreoretinopathy carry a life-long risk of progression. Therefore, it may be disadvantageous to use IVB alone, both for the increased burden of clinical examinations and re-treatments and for the benefit of peripheral retinal stabilization with laser retinopexy.
We observed beneficial effects attributable to IVB in patients treated for various other indications, including cystoid macular edema, choroidal hemangioma, and iris rubeosis. Iris neovascularization was reduced preoperatively to reduce intraoperative bleeding and improve dilation for retinal detachment repair in Xlinked retinoschisis, epithelial downgrowth, and persistent fetal vasculature. IVB alone was initially used unsuccessfully to reduce subretinal fluid in a patient with combined hamartoma of the retina and retinal pigment epithelium and another with a uveal coloboma. However, when subsequently combined with triamcinolone acetonide, both patients had a beneficial response.
There were significant limitations in our study, including the lack of standardization of treatment and safety data collection and selection bias. IVB was administered alone or in combination with other treatment modalities at the physicians' discretion. There were not control patients for comparison with conventional treatments. Our series represented a cohort of severely affected patients with poor visual acuity and anatomic compromise at baseline. This significantly limits comparison with patients not treated with IVB and the applicability of our statistical analysis. Patients with diffuse retinal processes such as Coats' disease and familial exudative vitreoretinopathy were more likely to have visual impairment and require surgery than patients with localized diseases such as CNV.
The authors believe IVB must be administered during a specific therapeutic window, whereas VEGF levels are elevated but prior to the development of significant fibrosis. Many of our patients already exceeded this window with prior or concurrent surgery for tractional retinal detachment. In this regard, it is remarkable that mean visual acuity was maintained at each time point. Although our follow-up was sufficient to demonstrate efficacy in some patients, longer followup is necessary to determine the long-term safety of IVB in children. The BLOCK-ROP and BEAT-ROP trials will provide prospective safety data collected in a standardized fashion on IVB in neonates.
IVB shows promise for several pediatric retinal and choroidal vascular diseases. The efficacy of IVB may differ among individual diseases and should not be generalized to all of the indications mentioned. IVB was most useful for reducing exudation and neovascularization, but did not have beneficial effects on fibrosis and traction. Although no systemic adverse events were observed, our study lacked the power to draw conclusions about safety. Further prospective, controlled trials using IVB for individual indications at earlier stages of disease are warranted.
